Tips for sleeping in an unfamiliar bed
from healthfinder.gov Daily News http://1.usa.gov/29x6FvQ
via How to Make Your Boobs Grow Naturally
Reference: Physical Fitness
from Tumblr http://bit.ly/297iE1W
Tips for sleeping in an unfamiliar bed
from healthfinder.gov Daily News http://1.usa.gov/29x6FvQ
via How to Make Your Boobs Grow Naturally
Reference: Physical Fitness
Problems triggered by misaligned or impacted third molars
from healthfinder.gov Daily News http://1.usa.gov/299C1ds
via How to Make Your Boobs Grow Naturally
Reference: Physical Fitness
Long-term exposure to air pollution may not only lead to respiratory and cardiovascular diseases, but also cause damage to the kidneys, a new study has warned.
To examine how particulate matter in the air is affecting kidney health, researchers from Southern Medical University in China analysed data on kidney biopsies taken over 11 years from 71,151 patients, encompassing all age groups.
On average, the likelihood of developing membranous nephropathy, an immune disorder of the kidneys that can lead to kidney failure, increased 13 per cent annually over the 11-year study period, whereas the proportions of other major kidney conditions remained stable, researchers said.
Regions with high levels of fine particulate air pollution had the highest rates of membranous nephropathy, they said.
“Our primary finding is that the frequency of membranous nephropathy has doubled over the last decade in China. We show that the increase corresponds closely with the regional distribution of particulate air pollution,” said Fan Hou from Southern Medical University.
The findings were published in the Journal of the American Society of Nephrology.
For older men who are facing lower sexual drive, erectile dysfunction and sperm production, undergoing testosterone therapy can prove to be beneficial, new research says.
Testosterone is a key male sex hormone involved in maintaining the sex urge.
Testosterone levels decline as men age and some men develop low testosterone levels and symptoms of sexual dysfunction.
“Our findings indicate low testosterone is one cause contributing to reduced libido and erectile dysfunction in older men,” said lead author Glenn R Cunningham from Baylor College of Medicine in the US.
“Men experiencing these symptoms should be evaluated for testosterone deficiency,” Cunningham added.
The findings showed that men treated with testosterone therapy displayed consistent improvement in libido.
Further, older men with symptoms of androgen deficiency showed improvement in their testosterone levels as well as more interest in sexual activity.
Androgen deficiency occurs when a man has consistently low levels of testosterone and resulting symptoms such as sexual dysfunction.
The study, published in The Journal of Clinical Endocrinology & Metabolism, was designed to investigate the effectiveness of testosterone therapy.
For the research, the team examined the effect of testosterone therapy on sexual function in a group of 470 men who were at least 65 years old and had low testosterone levels.
“For symptomatic older men with low testosterone levels, testosterone therapy led to consistent improvement in most types of sexual activity,” Cunningham concluded.
While syringes, pens, pumps and jet injectors have given diabetics options for their insulin delivery for many years now, a new device in the form of artificial pancreas could change the game within two years.
The device, which monitors blood glucose in patients with type 1 diabetes and then automatically adjusts levels of insulin entering the body, is likely to be available by 2018, concluded a team of researchers.
Issues such as speed of action of the forms of insulin used, reliability, convenience and accuracy of glucose monitors plus cybersecurity to protect devices from hacking, are among the issues that are being addressed.
Currently available technology allows insulin pumps to deliver insulin to people with diabetes after taking a reading or readings from glucose meters, but these two components are separate. It is the joining together of both parts into a ‘closed loop’ that makes an artificial pancreas, explain authors Roman Hovorka and Hood Thabit of the University of Cambridge, UK.
They added that in trials to date, users have been positive about how use of an artificial pancreas gives them ‘time off’ or a ‘holiday’ from their diabetes management, since the system is managing their blood sugar effectively without the need for constant monitoring by the user.
One part of the clinical need for the artificial pancreas is the variability of insulin requirements between and within individuals, on one day a person could use one third of their normal requirements, and on another 3 times what they normally would.
This is dependent on the individual, their diet, their physical activity and other factors. The combination of all these factors together places a burden on people with type 1 diabetes to constantly monitor their glucose levels, to ensure they don’t end up with too much blood sugar (hyperglycaemic) or more commonly, too little (hypoglycaemic). Both of these complications can cause significant damage to blood vessels and nerve endings, making complications such as cardiovascular problems more likely.
The actual timeline to availability of the artificial pancreas, as with other medical devices, encompasses regulatory approvals with reassuring attitudes of regulatory agencies such as the US Food and Drug Administration (FDA), which is currently reviewing one proposed artificial pancreas with approval possibly as soon as 2017. And a recent review by the UK National Institute of Health Research (NIHR) reported that automated closed-loop systems may be expected to appear in the (European) market by the end of 2018.
They concluded: “Significant milestones moving the artificial pancreas from laboratory to free-living unsupervised home settings have been achieved in the past decade. Through inter-disciplinary collaboration, teams worldwide have accelerated progress and real-world closed-loop applications have been demonstrated. Given the challenges of beta-cell transplantation, closed-loop technologies are, with continuing innovation potential, destined to provide a viable alternative for existing insulin pump therapy and multiple daily insulin injections.”
The study is published in Diabetologia.
While syringes, pens, pumps and jet injectors have given diabetics options for their insulin delivery for many years now, a new device in the form of artificial pancreas could change the game within two years.
The device, which monitors blood glucose in patients with type 1 diabetes and then automatically adjusts levels of insulin entering the body, is likely to be available by 2018, concluded a team of researchers.
Issues such as speed of action of the forms of insulin used, reliability, convenience and accuracy of glucose monitors plus cybersecurity to protect devices from hacking, are among the issues that are being addressed.
Currently available technology allows insulin pumps to deliver insulin to people with diabetes after taking a reading or readings from glucose meters, but these two components are separate. It is the joining together of both parts into a ‘closed loop’ that makes an artificial pancreas, explain authors Roman Hovorka and Hood Thabit of the University of Cambridge, UK.
They added that in trials to date, users have been positive about how use of an artificial pancreas gives them ‘time off’ or a ‘holiday’ from their diabetes management, since the system is managing their blood sugar effectively without the need for constant monitoring by the user.
One part of the clinical need for the artificial pancreas is the variability of insulin requirements between and within individuals, on one day a person could use one third of their normal requirements, and on another 3 times what they normally would.
This is dependent on the individual, their diet, their physical activity and other factors. The combination of all these factors together places a burden on people with type 1 diabetes to constantly monitor their glucose levels, to ensure they don’t end up with too much blood sugar (hyperglycaemic) or more commonly, too little (hypoglycaemic). Both of these complications can cause significant damage to blood vessels and nerve endings, making complications such as cardiovascular problems more likely.
The actual timeline to availability of the artificial pancreas, as with other medical devices, encompasses regulatory approvals with reassuring attitudes of regulatory agencies such as the US Food and Drug Administration (FDA), which is currently reviewing one proposed artificial pancreas with approval possibly as soon as 2017. And a recent review by the UK National Institute of Health Research (NIHR) reported that automated closed-loop systems may be expected to appear in the (European) market by the end of 2018.
They concluded: “Significant milestones moving the artificial pancreas from laboratory to free-living unsupervised home settings have been achieved in the past decade. Through inter-disciplinary collaboration, teams worldwide have accelerated progress and real-world closed-loop applications have been demonstrated. Given the challenges of beta-cell transplantation, closed-loop technologies are, with continuing innovation potential, destined to provide a viable alternative for existing insulin pump therapy and multiple daily insulin injections.”
The study is published in Diabetologia.
Consuming butter in limited quantities may not increase the risk of heart disease or stroke — and it might actually be slightly protective against diabetes, finds a new study.
The findings showed that patients suffering from heart problems or any related chronic diseases have no cause to worry as the increase in risk due to butter consumption was extremely small.
Butter has been found as a healthier choice in comparison to sugar and starch-enriched food like white bread or potatoes.
However, butter when spread on unhealthy foods like white bread may increase the risk of diabetes as well as cardiovascular diseases.
“Our results suggest that butter should neither be demonised nor considered ‘back’ as a route to good health,” said Dariush Mozaffarian, Associate Professor at Tufts University in the US.
On the other hand, consuming margarine and cooking oils rich in healthy fats such as soybean, canola, flaxseed and extra virgin olive oils are likely to lower the risks compared to butter or refined grains.
“Even though people who eat more butter generally have worse diets and lifestyles, it seemed to be pretty neutral overall,” said Laura Pimpin, Data Analyst at the UK Health Forum — a charitable health organisation, while adding that butter was a “middle of the road” food.
The study published in PLOS ONE, found mostly small or insignificant associations of each daily serving of butter with total mortality, cardiovascular disease and diabetes.
“More research is needed to better understand the observed potential lower risk of diabetes, which has also been suggested in some other studies of dairy fat,” the researchers noted.
The scientists conducted a study over a group of 6.5 million people from over 15 different countries.
Over the total follow up period, the combined group of studies included 28,271 deaths, 9,783 cases of cardiovascular disease and 23,954 cases of new-onset Type 2 diabetes.